Anthracycline-containing chemotherapy (A-CUT) can induce late cardiotoxicity adding a considerable burden to cardiovascular risk. Irradiation of left breast cancer has also been associated to an increased risk of cardiovascular disease. The aim of this observational study is to prove the usefulness of an accurate cardiovascular evaluation in left breast cancer survivors treated with radiotherapy (RT) and A-CUT. Patients with left breast cancer, on follow-up after treatment with A-CUT plus RT in an adjuvant setting, were eligible for this observational study. Patients underwent cardiovascular assessment with myocardial perfusion imaging. Thirty patients were enrolled in the study: mean age at diagnosis 55.8 years; stage: 11111; Er and/or pgR status: positive in 24/30 pts; 3 patients in pre-menopausal status. Twenty-two patients (73.3%) had normal perfusion imaging, 1 patient (3.3%) had a fixed myocardial perfusion defect, 7 patients (23.3%) had reversible myocardial perfusion defects; 1 patient (3%) with normal perfusion scan showed depressed rest and stress LVEF. Only 1 patient had a large defect and underwent coronary angiography and percutaneous coronary intervention. Five patients with small defect showed normal coronary arteries at Multislice Computed Tomography. Cardiovascular followup may reveal signs of A-CUT or RT-induced cardiotoxicity. A stress test combined with MPIand GATED-derived data of ventricular systolic performance after stress can give information on the coronary reserve and the contractile reserve and allow early appropriate treatment.
tyrosine kinase receptor effective in early-stage HER2 positive breast cancer. While anthracyclines cause irreversible damage, with myocyte death (Type I chemotherapy-related cardiac dysfunction), trastuzumab usually causes totally reversible cell dysfunction, with no pathologic changes (type II dysfunction) (3) . Aromatase inhibitors can induce potentially dangerous modifications in lipid profiles, thus enhancing cardiovascular mortality in women (4) (5) . Radiation therapy (RT) reduces local recurrences and improves survival in all surgical settings, both after lumpectomy and mastectomy (6) . Radiotherapy for left breast cancer may induce clinical manifestation of coronary artery disease (CAD) and myocardial perfusion defects, which may be fixed (irreversible) or stress-induced (reversible) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . A significant increase in non-cancer death has been shown in long-term survivors of breast cancer: in this population there is an interplay between cancer therapy-induced cardiotoxicity and the cardiovascular risk factors of the population (17) (18) . The aim of this observational study is to prove the usefulness of an accurate cardiovascular evaluation in left breast cancer survivors treated with RT and A-CHT. A close cardiologic follow-up was achieved collecting clinical, electrocardiographic and echocardiograhic data and performing myocardial perfusion imaging (MPI) both at rest and after stress by Gated SPECT. In patients presenting myocardial perfusion defects, coronary imaging was obtained either non-invasively by Multislice Computed Tomography or invasively by coronary angiogram. The results regarding thirty consecutive patients are presented.
MATERIALS AND METHODS

Study population
Patients with left breast cancer on follow-up after treatment with A-CHT and RT in an adjuvant setting were eligible for this observational study. We recruited consecutive patients on oncologic follow-up. Thirty-four consecutive patients were enrolled, two patients refused consent to the study, and 2 patients were lost at follow-up. We examined data from thirty patients. All patients gave informed consent.
The patients had the following characteristics (Table  I) : mean age at diagnosis 55.8 years (38-69);stage I: 5 patients; stage IIA: 15 patients; stage lIB: 5 patients; stage III: 5 patients. Twenty-two patients had quadrantectomy and Iymphonodal axillary dissection, 6 left mastectomy, 2 bilateral quadrantectomy. Four patients were treated with neadjuvant chemotherapy. Er and/or pgR status was positive in 24/30 patients, 3 patients were in premenopausal status. Twelve patients received FEClike and 18 sequential chemotherapy: EC for 4 cycles and Taxans for others 4 cycles. Cumulative dose of antracycline was from a minimum of 360 mg/m2 to a maximum of 540 mg/m2. Trastuzumab was administered to 2 patients. Hormone receptor-positive patients received hormonotherapy: 3 tamoxifen 20 mg/die plus LHRH analogs, 8 tamoxifen for 2 years and aromatase inhibitors for 3 years. All 30 patients were treated with RT. Patients treated with breast conserving surgery (22) received tangential photons to the left breast and 6-9 MV electron boost to the tumor bed with a total irradiation dose of 60 gray (Gy) in 6 weeks. Patients treated after mastectomy (6) received tangential photons to chest wall (4), tangential photons to chest wall and 6 MV internal mammary chain irradiation (I patient), 12 MV electron radiation treatment to chest wall (I patient) with a total irradiation dose of 50 Gy and a duration of treatment of 5 weeks. Two patients with bilateral breast cancer received tangential photons to left breast and 6 MY boost to tumour bed with a total irradiation dose of 60 Gy. Some patients received supraclavicular irradiation, but we do not specify the radiation dose because it does not affect the results of this study.
As far as cardiologic profile is concerned, in our population study 16 patients were hypertensive, 17 had values of total cholesterol above 200 mg/dl, 2 had a history of smoking, one was an active smoker, 1 patient was diabetic, and I patient had impaired glucose tolerance.
Imaging modalities
The echocardiographic examination was performed using a Hitachi Logos CVX Echocardiograph. The evaluation included the assessment of left ventricular ejection fraction (area-length), left ventricular diastolic filling as well as the valvular function.
All patients underwent single-day stress-rest 99mTctetrofosmin MPI by gated SPECT according to the European Association of Nuclear Medicine and European Society of Cardiology recommendations (19) . A treadmill standardized protocol was carried out monitoring heart rate, rhythm, blood pressure and electrocardiographic ventricular repolarization. Recognized stress test endpoints were adopted to terminate the test. At peak exercise for additional 90-120 sec thereafter 370 MBq of 99mTc-tetrofosmin were injected intravenously and patients sustained the exercise for additional 90-120 s 
RESULTS
We examined data from thirty patients with left breast cancer treated with A-CHT and RT. Patients had no records of ECG ventricular repolarization abnormalities nor did they present echocardiographic LVEF impairment before cancer treatment (Table II) .
Cardiologic follow-up was performed at a median time of 33.76 months from surgery. All patients underwent cardiologic evaluation, recording risk factors for CAD and HF, registration of ECG, echocardiographic examination and singleday stress-rest 99mTc-tetrofosmin MPI by gated SPECT.
.. At follow-up the electrocardiogram showed sinus rhythm in almost all patients. One patient presented atrial fibrillation, while most of the patients had some abnormalities of ventricular repolarization (generally negative T waves). One patient had slight ST elevation in V2-V3 with negative T wave in aVL, V2-V6 mimicking anterior transmural ischemia, and another showed q waves in inferior leads and negative T waves in V2-V3.
Echocardiographic evaluation showed normal LVEF in 27 patients, two patients had mild (LVEF 0.50) or moderate (LVEF 0.40) left ventricular dysfunction, for one patient echocardiographic evaluation was not possible due to bad acoustic window.
One patient had mild mitral stenosis, 3 patients had septal hypertrophy, 29 patients had abnormalities of diastolic function (mitral valve).
SPECT was performed at a mean time of 34.36 months after RT. Twenty-two patients (73.3%) had normal perfusion imaging, I patient (3.3%) had fixed myocardial perfusion defects, 7 patients (23.3%) had reversible, stress-induced, myocardial perfusion defects, mostly in the apical regions, while one patient with no myocardial perfusion defects showed depressed LVEF.
One patient with a large stress-induced perfusion defect in the LV apical region was referred for coronary angiography: a significant lesion of a marginal coronary vessel was found and it was treated with PTCA. The patient had risk factors for CAD: hypertension and hypercholesterolemia and a history of atypical chest pain. A pre-RT perfusion scan was normal but in this case there might have been an overlapping effect between the patient risk factors and the cardiotoxicity of both anthracycline and left thoracic radiotherapy. Six patients had small stress-induced defects.
Two patients with no risk factors for CAD showed small stress-induced myocardial perfusion defects (postero-septal and apical anterior region), their Multislice Computed Tomography coronary imaging was normal. One hypertensive patient showed a small antero-lateral myocardial perfusion defect 3 months after the end of RT, the SPECT was scheduled because of rest ECG abnormalities, she had no symptoms and a normal Multislice Computed Tomography coronary imaging.
Two patients with risk factors for CAD (hypertension and hypercholesterolemia) showed small reversible perfusion defects: I patient in the infero-lateral region, the other in the anterolateral region ( Fig. I) that disappeared in a control SPECT performed after 2 years. Multislice Computed Tomography coronary imaging was not suggested. The patient with fixed defect in the apical segment of the inferolateral region was a hypertensive, hypercholesterolemic woman, she had also a Multislice Computed Tomography coronary imaging that showed a normal coronary tree, with a small circumflex artery.
Patients with small myocardial perfusion defects and normal non-invasive coronary imaging did not experience clinical events consistent with CAD.
GATED SPECT was performed on 23 patients (76%). Stress and rest comparison of ventricular function was possible in 6 patients: post-stress EF increased in 3 patients and showed a slight reduction of EF in 3 patients, in this last subset one'patient was hypertensive, the other two had no risk factors for coronary artery disease or congestive heart failure, it can be inferred that the toxic long-lasting effects of anthracycline might have blunted the contractile response. The damage to the myocites did not affect the global function at rest, but reduced the physiological response to physical exercise.
All patients are still alive, 2 patients had cancer progression.
Case study
One patient, a 35-year-old woman with no risk factors for CAD and marked abnormalities of ventricular repolarization mimicking anterior ischemia, had a perfusion scan showing reversible myocardial perfusion defects in the distal anterolateral and distal anteroseptal region that were persistent after 2 years. She had not undergone a myocardial perfusion scan before anti-cancer therapy, but her ECG before breast surgery and before chemotherapy was normal. After the last SPECT, post stress EF was 47%. Since LVEF before chemotherapy was normal, it can be inferred that the electrocardiographic abnormalities and the myocardial perfusion defect may represent signs of A-CHT and RT-induced myocardial damage. The patient was scheduled for Multislice Computed Tomography, but she refused the procedure. She also developed atrial flutter at the age of 38 and she is now taking anti-arrhythmic drug and angiotensin receptor blocking agents. She might have developed some damage both to the left ventricle and to the atria, causing left ventricular perfusion defects, atrial fibrosis with electrical disorder and supraventricular arrhythmias. She has not presented any symptoms of coronary artery disease or heart failure to date.
DISCUSSION
Cancer therapies are known to cause cardiotoxicity, mainly in terms of heart failure and coronary artery disease. Thoracic radiotherapy improves overall survival, but the survival gain may be diminished by RT-associated cardiac mortality: epidemiology studies have shown that radiation is an independent risk factor for death from cardiovascular disease even more than 10 years after the treatment. Old RT techniques resulted in incidental irradiation of large volumes of the heart and determined an increased risk of cardiac morbidity and mortality. More modern RT techniques limit cardiac exposure and seem to be safer, but some Authors have shown that even RT delivered with modern techniques can determine myocardial perfusion defects (7) (8) (9) (10) (11) (12) (13) (14) (15) the clinical significance of which is still incompletely known. In particular, RT for left-sided breast cancer has been associated with increased perfusion defects at 6 months in the left anterior descending artery distribution. Factors related to the extent of perfusion defects include the percent of irradiated left ventricle, hormonal treatment and pre-RT hypercholesterolemia (16) . According to a recent paper on RT-induced cardiac and cerebral toxicity, radiation is considered to be an independent risk factor for cardiovascular and cerebrovascular disease in cancer patients (20) . Myocardial damage seems to be due to microthrombi and occlusion of vessels caused in primis by inflammatory modifications of microvascular vessel endothelium. This inflammatory response may be increased in the presence ofhypercholesterolemia, thus leading to the atherosclerotic process. The microvascular genesis of myocardial perfusion defects in our patients is confirmed by the normality of epicardial coronary arteries at Multislice Computed Tomography. All these observations stress the importance of a close cardiologic follow-up: adjuvant therapies may have overlapping and additive cardiac effects and they do have an impact on female pre-existing cardiac risk factors. Age is an important risk factor and it is increasingly important since the population ofbreast cancer patients is becoming older (18) . To avoid the "multiple hit phenomenon", as Jones et al. called this combined form of cardiovascular injury, it is necessary to screen for concomitant risk factors and for early signs of cardiotoxicity (21) . The clinical utility of the left ventricular ejection fraction (LVEF) has been questioned by Ewer (22) . Troponin release during high dose anthracycline administration has been shown to be a powerful predictor of cardiac events (23-24), but neither ejection fraction at rest, nor troponin release can tell us if there is any impairment in myocardial contractile reserve. Our data seem to suggest that GATED-derived estimation of LVEF at rest and after stress gives significant information about the myocardial contractile reserve. The blunted response of EF to stress that we observed in some patients (mostly hypertensive patients) may represent an early sign of myocardial damage and warrant pharmacological treatment. We do not have baseline myocardial scintigraphy for our patients, but 3 of the patients with myocardial perfusion defects had no risk factors for coronary artery disease and their ECG and echocardiographic findings before cancer therapy were normal, and in these patients we might infer that the small perfusion defects observed at SPECT scintigraphy can represent RT-induced microvascular damage (indeed, for 2 of them the Multislice Computed Tomography was normal).
Patients treated for breast cancer in adjuvant setting should be considered in ACC/AHA Stage A Heart Failure (25) , that is to say patients at high risk for cardiovascular disease. Gender-specific unique features of cardiovascular risk factors must be taken into account when dealing with survivors of breast cancer. Perik PJ et al. showed higher circulating levels of apoptotic proteins when compared to age-matched healthy controls in disease-free breast cancer survivors. Circulating apoptotic proteins increase in patients with heart failure unrelated to anticancer treatment (26) . These results seem to indicate that breast cancer patients live in some sort of "pre-heart-failure status" and they are mostly asymptomatic before overt coronary artery disease or congestive heart failure become clinically evident. We have to make all efforts to reduce the impact of iatrogenic cardiovascular disease in this population and this goal can be achieved only through a very strict collaboration between oncologists and cardiologists: a cardio-oncology team could offer the best care for breast cancer patients.
